Heat Biologics is a clinical-stage company focused on developing its proprietary "ImPACT" (Immune Pan-Antigen Cytotoxic Therapy), a fully allogeneic (“off-the-shelf”) cell-based immunotherapy for use in the treatment of a wide range of cancers.
The Company's ImPACT therapy is a first-in-class, fully human immunotherapy that functions as both an immune stimulator and an antigen-delivery system. ImPACT effectively transforms living allogeneic cells into "osmotic pumps" that continuously secrete cancerous antigens to robustly stimulate the immune system against the targeted cancer. This therapy is applicable to a wide range of cancers.
Heat is currently conducting multiple clinical trials in two indications with its ImPACT therapy based products, HS-410 to treat Non-Muscle Invasive Bladder Cancer (NMIBC) and HS-110 to treat Non-Small Cell Lung Cancer (NSCLC).

TypePublic
HQDurham, US
Founded2008
Size (employees)19 (est)
Websiteheatbio.com
Heat Biologics was founded in 2008 and is headquartered in Durham, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Heat Biologics Office Locations

Heat Biologics has an office in Durham
Durham, US (HQ)
12 801 Capitola Dr
Show all (1)
Report incorrect company information

Heat Biologics Financials and Metrics

Heat Biologics Revenue

USD

Net income (Q2, 2018)

(8 m)

EBIT (Q2, 2018)

(8.1 m)

Market capitalization (21-Sep-2018)

45.3 m

Closing stock price (21-Sep-2018)

2

Cash (30-Jun-2018)

24.7 m
Heat Biologics's current market capitalization is $45.3 m.
Annual
USDFY, 2013FY, 2014FY, 2016FY, 2017

General and administrative expense

2.4 m4 m4.1 m6.4 m

R&D expense

2.7 m2.9 m9.3 m8.3 m

Operating expense total

5.2 m6.8 m13.5 m14.9 m

EBIT

(6.6 m)(12.2 m)(13.1 m)(13.3 m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

General and administrative expense

1 m832.1 k1.3 m893.2 k947.4 k1 m1.1 m820.6 k1.5 m1.8 m3.1 m

R&D expense

849.4 k1 m503.6 k587.2 k677.2 k500.2 k454.9 k559.2 k1.8 m2.9 m6.4 m

Operating expense total

1.9 m1.9 m1.8 m1.5 m1.6 m1.5 m1.5 m1.4 m3.3 m4.7 m10 m

EBIT

(3 m)(3.1 m)(4 m)(4.9 m)(5.3 m)(4.7 m)(2.9 m)(2.3 m)(3.3 m)(3.9 m)(8.1 m)
Annual
USDFY, 2013FY, 2014FY, 2016FY, 2017

Cash

4.6 m3.7 m7.8 m9.8 m

Accounts Receivable

1.8 m82.3 k14.8 k

Inventories

1.7 m

Current Assets

23 m15.3 m8.3 m11.7 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Cash

6 m3.3 m10.3 m11.5 m8.2 m10 m7.1 m8.5 m11.1 m9 m24.7 m

Accounts Receivable

131.8 k2 k5.4 k14.3 k

Current Assets

17.6 m16.1 m22.2 m20.2 m15.9 m12.5 m7.6 m9.1 m11.4 m10.6 m28.7 m

PP&E

480.9 k464.3 k428.2 k495 k468 k444.4 k423.7 k392.9 k332 k662 k645.7 k
Annual
USDFY, 2013FY, 2014FY, 2016FY, 2017

Net Income

(6.6 m)(12.2 m)(13 m)(12.4 m)

Depreciation and Amortization

6.3 k66.9 k132.1 k134.1 k

Inventories

10 k

Accounts Payable

(1.7 m)(175.9 k)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(3 m)(3.1 m)(4 m)(8.9 m)(14.4 m)(4.7 m)(7.8 m)(9.4 m)(3.2 m)(3.7 m)(8 m)

Depreciation and Amortization

25.6 k53.9 k84.4 k32.4 k65.6 k98.8 k33.1 k44.1 k108.4 k

Accounts Payable

720.1 k680.5 k(555.6 k)(570 k)(385.2 k)(494.3 k)(1.5 m)(1.5 m)442 k667.6 k(211.9 k)

Cash From Operating Activities

(4.5 m)(8.2 m)(12.4 m)(4.9 m)(8.9 m)(10.8 m)(3 m)(3.8 m)(11.8 m)
USDY, 2018

Financial Leverage

1.5 x
Show all financial metrics
Report incorrect company information

Heat Biologics Online and Social Media Presence

Embed Graph
Report incorrect company information

Heat Biologics Company Life and Culture

Report incorrect company information